ArticleAntimicrobial agents and chemotherapy2010
Therapeutic potential of a combination of two gene-specific small interfering RNAs against clinical strains of Acanthamoeba.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Antibiofilm activity of cationic carbosilane BD132 dendron and its synergistic effect with amphotericin B against Candida spp.Scientific reports · 2025Article
- Assessment ofJournal of water and health · 2024Article
- Amoebicidal and cysticidal in vitro activity of cationic dendritic molecules against Acanthamoeba polyphaga and Acanthamoeba griffini.Parasitology research · 2024Article
- In Vitro Cytopathogenic Activities ofPathogens (Basel, Switzerland) · 2022Article
- Amoebicidal activity of cationic carbosilane dendrons derived with 4-phenylbutyric acid against Acanthamoeba griffini and Acanthamoeba polyphaga trophozoites and cysts.Scientific reports · 2022Article
- Antiamoebic Activity of Imidazothiazole Derivatives against Opportunistic PathogenAntibiotics (Basel, Switzerland) · 2022Article
- Article
- Drug Discovery againstPathogens (Basel, Switzerland) · 2020Review
- Whole Organism Model to Study Molecular Mechanisms of Differentiation and Dedifferentiation.Biology · 2020Article
- Combined Amoebicidal Effect of Atorvastatin and Commercial Eye Drops againstPathogens (Basel, Switzerland) · 2020Article
- Antioxidant and Leishmanicidal Evaluation ofPathogens (Basel, Switzerland) · 2019Article
- Amebicidal effects of fenugreek (Food science & nutrition · 2019Article
- Leishmanicidal activity of α-bisabolol from Tunisian chamomile essential oil.Parasitology research · 2018Article
- Assessment of the antiprotozoal activity of Pulicaria inuloides extracts, an Algerian medicinal plant: leishmanicidal bioguided fractionation.Parasitology research · 2018Article
- Amoebicidal Activity of Caffeine and Maslinic Acid by the Induction of Programmed Cell Death in Acanthamoeba.Antimicrobial agents and chemotherapy · 2017Article
- Perifosine Mechanisms of Action in Leishmania Species.Antimicrobial agents and chemotherapy · 2017Article
- Programmed cell death in Acanthamoeba castellanii Neff induced by several molecules present in olive leaf extracts.PloS one · 2017Article
- A Review of the Current Research Trends in the Application of Medicinal Plants as a Source for Novel Therapeutic Agents AgainstIranian journal of pharmaceutical research : IJPR · 2016Article
- In vitro activities of hexaazatrinaphthylenes against Leishmania spp.Antimicrobial agents and chemotherapy · 2015Article
- Evaluation of Acanthamoeba myosin-IC as a potential therapeutic target.Antimicrobial agents and chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenic strains of the genus Acanthamoeba are causative agents of severe infections, such as fatal encephalitis and a sight-threatening amoebic keratitis. Antimicrobial therapy for these infections is generally empirical, and patient recovery is often problematic, due to the existence of a highly resistant cyst stage in these amoebae. In previous studies, small interfering RNAs (siRNAs) against the catalytic domains of extracellular serine proteases and glycogen phosphorylase from Acanthamoeba were designed and evaluated for future therapeutic use. The silencing of proteases resulted in Acanthamoeba failing to degrade human corneal cells, and silencing of glycogen phosphorylase caused amoebae to be unable to form mature cysts. After the siRNA design and concentration were optimized in order to avoid toxicity problems, cultures of Acanthamoeba were treated with a combination of both siRNAs, and cells were evaluated under an inverted microscope. This siRNA-based treatment dramatically affected the growth rate and cellular survival of the amoebae. These results were observed less than 48 h after the initiation of the treatment. In order to check possible toxic effects of the siRNA combination, three eukaryotic cell lines (HeLa, murine macrophages, and osteosarcoma cells) were treated with the same molecules, and cytotoxicity was examined by measuring lactate dehydrogenase release. The future use of the combination of these siRNAs is proposed as a potential therapeutic approach against pathogenic strains of Acanthamoeba.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.